Search clinical trials for: Transitionel cell cancer of the urothelium

Total 455608 results

AstraZeneca

Completed

Phase II Gemcitabine + Cisplatin +/- Iressa Bladder CCT

Bladder Cancer

Germany
Shanghai Miracogen Inc.

Recruiting

A Study of MRG002 in the Treatment of HER2-positive Unresectable Locally Advanced or Metastatic Urothelium Cancer

Metastatic Urothelial Carcinoma | Locally Advanced Urothelial Cancer

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant

Bladder Cancer | Urethral Cancer | Urachal Cancer

United States
M.D. Anderson Cancer Center

Active, not recruiting

Prophylactic Cranial Irradiation (PCI) for Small Cell Carcinoma of the Urothelium

Bladder Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction

Metastatic Urothelial Carcinoma | Stage III Bladder Urothelial Carcinoma AJCC v6 and v7 | Stage IV Bladder Urothelial Carcinoma AJCC v7 | Locally Advanced Urothelial Carcinoma | Recurrent Urothelial Carcinoma | Unresectable Urothelial Carcinoma | Advanced Urothelial Carcinoma

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Completed

Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer

High Grade Upper Tract Urothelial Carcinoma

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter | Urethral Cancer

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI); Cancer and Leukemia Group B

Completed

Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter | Urethral Cancer

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium and Decreased Kidney Function

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter | Urethral Cancer

United States
Jonsson Comprehensive Cancer Center
Merck Sharp & Dohme LLC

Completed

Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate

Urothelial Carcinoma | Castration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Metastatic Bladder Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Stage III Bladder Cancer AJCC v8 | Stage III Urethral Cancer AJCC v8 | Stage IV Bladder Cancer AJCC v8 | Stage IV Urethral... and other conditions

United States
Memorial Sloan Kettering Cancer Center
Novartis Pharmaceuticals

Completed

Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium

Bladder Cancer | Metastatic Transitional Cell Carcinoma

United States
Eli Lilly and Company
Merck Sharp & Dohme LLC

Completed

A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer

Carcinoma, Transitional Cell | Gastric Adenocarcinoma | Non-small Cell Lung Cancer | Biliary Tract Cancer | Adenocarcinoma of the Gastroesophageal Junction

Germany, United States, Spain, United Kingdom, France, Japan
Eisai Inc.
PharmaBio Development Inc.

Terminated

Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer

Bladder Cancer

United Kingdom, Netherlands, Spain, Germany, United States, Ukraine
Memorial Sloan Kettering Cancer Center
Novartis

Completed

Buparlisib in Metastatic Transitional Cell Carcinoma of the Urothelium

Metastatic Transitional Cell Carcinoma of the Urothelium

United States
Cardiff University

Completed

Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium (SUCCINCT)

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter | Urethral Cancer

United Kingdom
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

Gemcitabine, Paclitaxel, and Cisplatin in Treating Patients With Advanced Cancer of the Urothelium

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

Biomarkers in Patients With Kidney Cancer or Cancer of the Urothelium and in Healthy Participants

Kidney Cancer | Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter | Urethral Cancer

United States
Cardiff University

Completed

Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter | Urethral Cancer

United Kingdom
European Organisation for Research and Treatment...
National Cancer Institute (NCI); NCIC Clinical Trials Group; Institute of Cancer... and other collaborators

Completed

Comparison of Immediate and Delayed Adjuvant Chemotherapy in Treating Patients Who Have Undergone a Radical Cystectomy for Stage III or Stage IV Transitional Cell Carcinoma of the Bladder Urothelium

Stage III Bladder Cancer | Stage IV Bladder Cancer | Transitional Cell Carcinoma of the Bladder
Hopital Foch

Completed

The Efficacy of RAD 001 as Second Line Therapy in Patients With Transitional Cell Carcinoma TCC of the Urothelium (AFINIVEST)

Urothelial Cancer

France
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI); Pfizer

Completed

Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter | Urethral Cancer

United States
Bristol-Myers Squibb

Completed

First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy

Transitional Cell Carcinoma | Bladder Cancer | Metastasis

United States, Korea, Republic of, United Kingdom, Spain, Australia, France, Thailand, Denmark, Poland, Belgium, Italy, Philippines, Canada, Russian Federation, Greece, Indonesia
M.D. Anderson Cancer Center
AstraZeneca

Terminated

Iressa and Taxotere Study in Patients With Metastatic Urothelial Cancer

Bladder Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Short-Term Low-Dose Interferon Alfa in Treating Patients With Cancer of the Urothelium

Bladder Cancer | Urethral Cancer

United States
Queen Mary University of London
GlaxoSmithKline

Unknown

A Double Blind Randomised Study of Lapatinib and Placebo in Metastatic TCC of the Urothelium (LaMB)

Bladder Cancer

United Kingdom
National Cancer Institute (NCI)

Terminated

Vorinostat in Treating Patients With Locally Recurrent or Metastatic Cancer of the Urothelium

Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter | Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter | Regional Transitional Cell Cancer of the Renal Pelvis and Ureter | Transitional Cell Carcinoma of the Bladder | Localized Transitional Cell Cancer of the...

United States
National Cancer Institute (NCI)

Completed

VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium

Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter | Recurrent Bladder Cancer | Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter | Stage III Bladder Cancer | Stage IV Bladder Cancer | Transitional Cell Carcinoma of the Bladder | Adenocarcinoma of the Bladder | Distal... and other conditions

United States
National Cancer Institute (NCI)

Terminated

Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium

Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter | Recurrent Bladder Cancer | Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter | Regional Transitional Cell Cancer of the Renal Pelvis and Ureter | Stage III Bladder Cancer | Stage IV Bladder Cancer | Transitional... and other conditions

United States
Amgen

Unknown

Combination Chemotherapy Plus Filgrastim in Treating Patients With Locally Recurrent or Advanced Urothelium Cancer

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter

United States
European Organisation for Research and Treatment...

Completed

Combination Chemotherapy in Treating Patients With Transitional Cell Cancer of the Urothelium

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter | Urethral Cancer

Netherlands, Spain, United Kingdom, Poland, Belgium, Denmark, Hungary, Germany, Israel, Italy, Austria
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0219, Combination Chemotherapy Followed By Observation or Surgery in Patients With Stage II or Stage III Cancer of the Urothelium

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter | Urethral Cancer

United States
National Cancer Institute (NCI)

Terminated

Trastuzumab in Treating Patients With Previously Treated, Locally Advanced, or Metastatic Cancer of the Urothelium

Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter | Recurrent Bladder Cancer | Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter | Stage IV Bladder Cancer | Transitional Cell Carcinoma of the Bladder | Distal Urethral Cancer | Proximal Urethral Cancer | Recurrent... and other conditions

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0121, Neoadjuvant Carboplatin, Paclitaxel, and Gemcitabine Followed by Cisplatin and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Carcinoma of the Urothelium

Bladder Cancer | Urethral Cancer

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0306, Irinotecan in Treating Patients With Recurrent or Refractory Advanced Transitional Cell Cancer of the Urothelium Previously Treated With Chemotherapy

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter | Urethral Cancer
Southwest Oncology Group
National Cancer Institute (NCI)

Terminated

S0400, FR901228 in Treating Patients With Advanced Cancer of the Urothelium

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter | Urethral Cancer
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Neoadjuvant Ifosfamide, Doxorubicin, Gemcitabine, and Cisplatin in Treating Patients Who Are Undergoing Radical Cystectomy for Locally Advanced Carcinoma (Cancer) of the Urothelium

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter | Urethral Cancer

United States
Bristol-Myers Squibb
Pierre Fabre Medicament

Completed

Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium

Kidney Neoplasms | Transitional Cell Carcinoma | Bladder Cancer | Bladder Neoplasms | Ureter Neoplasms | Neoplasm, Bladder

United States, Spain, Italy, Canada, Indonesia, Singapore, Australia, Austria, France, Greece, Korea, Republic of, Philippines, Sweden, Switzerland, Thailand
Achieve Life Sciences

Completed

TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the Urothelium

Carcinoma, Transitional Cell | Ureteral Neoplasms | Urethral Neoplasms | Bladder Neoplasms

United States
Eli Lilly and Company

Completed

A Phase 2 Trial of ALIMTA (Pemetrexed) Plus Gemcitabine in Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium

Urologic Neoplasms

Finland, France, Germany
Eli Lilly and Company

Completed

A Phase 2 Trial of ALIMTA (Pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium

Urologic Neoplasms | Metastases, Neoplasm

United States
Bristol-Myers Squibb

Not yet recruiting

Patient and Physician Preference Study in Resectable, Non-small Cell Lung Cancer Treatments

Non-small Cell Lung Cancer (NSCLC)

United Kingdom
Jonsson Comprehensive Cancer Center

Not yet recruiting

PH Weighted Chemical Exchange Saturation Transfer MRI-Based Surgical Resection to Improve Survival in Patients With Glioblastoma

Glioblastoma

United States
Pfizer

Recruiting

A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination (LTbR)

Melanoma | Colorectal Cancer | Non-Small Cell Lung Cancer | Urothelial Cancer | Advanced or Metastatic Solid Tumors

United States, Puerto Rico
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia

Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia

United States
BioNTech SE

Not yet recruiting

Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy

Small-cell Lung Cancer | Extensive-stage Small-cell Lung Cancer
Pfizer

Not yet recruiting

A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

Carcinoma, Non-Small-Cell Lung | Colorectal Neoplasms | Carcinoma, Pancreatic Ductal
Merck Sharp & Dohme LLC

Not yet recruiting

Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)

Esophageal Cancer | Esophageal Neoplasms | Gastroesophageal Adenocarcinoma | Gastroesophageal Junction
Shanghai East Hospital

Recruiting

Chemokine and Co-stimulatory Molecule-modified Mesenchymal Stem Cells for the Treatment of Advanced Colorectal Cancer

Advanced Colorectal Cancer

China
Rong Tao
Novatim Immune Therapeutics (Zhejiang) Co., Ltd.

Recruiting

CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL

Acute Lymphoblastic Leukemia, in Relapse | B-cell Lymphoma Refractory | B-cell Lymphoma Recurrent | Acute Lymphoblastic Leukemia With Failed Remission

China
First Affiliated Hospital of Zhejiang University

Recruiting

Efficacy and Safety of Modified Si Jun Zi Tang in Perioperative NSCLC Treatment (MSJZT-NSCLC)

Non Small Cell Lung Cancer | Perioperative Complication

China

Search clinical trials for: Transitionel cell cancer of the urothelium

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mali

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations